利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.039 秒)

    Identification and engineering of antibodies with variant Fc regions and methods of using same
    1.
    发明授权
    Identification and engineering of antibodies with variant Fc regions and methods of using same 有权
    具有变体Fc区的抗体的鉴定和工程及其使用方法

    公开(公告)号：US08445645B2

    公开(公告)日：2013-05-21

    申请号：US13158169

    申请日：2011-06-10

    申请人： Jeffrey Stavenhagen ,  Sujata Vijh ,  Christopher Rankin ,  Sergey Gorlatov ,  Ling Huang

    发明人： Jeffrey Stavenhagen ,  Sujata Vijh ,  Christopher Rankin ,  Sergey Gorlatov ,  Ling Huang

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40

    CPC分类号： A61K39/39558 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/005 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734

    摘要： The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

    摘要翻译： 本发明涉及包括变体Fc区的分子，特别是多肽，更特别是免疫球蛋白（例如，抗体），其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰，所述变体Fc区 相对于包含野生型Fc区的可比较分子，以更大的亲和力结合FcγRIIIA和/或FcγRIIA。 本发明的分子特别可用于预防，治疗或改善与疾病，病症或感染相关的一种或多种症状。 本发明的分子特别可用于治疗或预防需要通过FcγAMR介导的效应细胞功能增强的功效（例如ADCC）的疾病或病症，例如癌症，感染性疾病和增强治疗功效 的治疗性抗体，其作用由ADCC介导。

    Diagnostic screens for Alzheimer's disease
    2.
    发明授权
    Diagnostic screens for Alzheimer's disease 有权
    阿尔茨海默病诊断屏

    公开(公告)号：US08377640B2

    公开(公告)日：2013-02-19

    申请号：US12870987

    申请日：2010-08-30

    申请人： Zsuzsanna Nagy

    发明人： Zsuzsanna Nagy

    IPC分类号： C12Q1/68

    CPC分类号： G01N33/6896 ,  G01N2800/2821

    摘要： The present invention relates diagnostic screens for Alzheimer's disease, and in particular to diagnostic tests based on screening for the presence of cellular changes that occur early in the pathology of Alzheimer's disease.

    摘要翻译： 本发明涉及阿尔茨海默氏病的诊断筛选，特别涉及基于在阿尔茨海默病病理学早期发生的细胞变化的筛选的诊断测试。

    Inhibition of ornithine aminotransferase for the treatment of proliferative disorders
    4.
    发明授权
    Inhibition of ornithine aminotransferase for the treatment of proliferative disorders 有权
    抑制鸟氨酸氨基转移酶治疗增殖性疾病

    公开(公告)号：US08211865B2

    公开(公告)日：2012-07-03

    申请号：US12377889

    申请日：2007-08-20

    申请人： Yaron Ilan ,  Ehud Zigmond ,  Richard B. Silverman ,  Hejun Lu

    发明人： Yaron Ilan ,  Ehud Zigmond ,  Richard B. Silverman ,  Hejun Lu

    IPC分类号： A61K48/00

    CPC分类号： A61K31/196 ,  A61K31/198

    摘要： The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject.

    摘要翻译： 本发明涉及抑制鸟氨酸氨基转移酶（OAT）抑制肿瘤细胞增殖。 更具体地说，本发明涉及通过选择性抑制OAT来治疗增殖性疾病的方法，并进一步提供使用OAT抑制剂，特别是5-氨基-1,3-己二烯基羧酸（Gabaculine）和加珠菌素类似物 8，用于治疗增殖性疾病如肝细胞癌的组合物和方法。 本发明还基于确定从受试者获得的生物样品中表达的OAT水平，提供用于诊断哺乳动物受试者中病理性增殖性病症的方法和试剂盒。

    System and method for measuring and recording skull vibration in situ
    8.
    发明授权
    System and method for measuring and recording skull vibration in situ 有权
    用于测量和记录头骨颅骨振动的系统和方法

    公开(公告)号：US08376967B2

    公开(公告)日：2013-02-19

    申请号：US12759206

    申请日：2010-04-13

    申请人： Barry L. Mersky

    发明人： Barry L. Mersky

    IPC分类号： H04R29/00 ,  H04R25/00 ,  A61B5/00 ,  A61B5/103 ,  A61B5/11

    CPC分类号： H04R25/604 ,  A61B5/11 ,  A61B5/682 ,  H04R25/48

    摘要： A method and apparatus for measuring and recording skull vibration in situ comprising a receiving means, a dental material capable of filling any gaps between the receiving means and the at least one tooth, the material capable of transmitting mechanical vibration within the dental bone conduction pathway to the receiving means; a transducer mounted into or unto the receiving means said transducer capable of transducing mechanical vibration within the dental bone conduction pathway into electrical signals; an extra-orally recordation hardware and software capable of receiving and processing said electrical signals from said transducer.

    摘要翻译： 一种用于测量和记录原位颅骨振动的方法和装置，包括接收装置，能够填充接收装置和至少一个牙齿之间的任何间隙的牙科材料，能够将牙齿传导通路内的机械振动传递到 接收装置; 安装在所述接收装置中或所述接收装置上的换能器，所述换能器能够将所述牙科骨传导通路内的机械振动转换成电信号; 能够接收和处理来自所述换能器的所述电信号的外部口头记录硬件和软件。

    Engineering Fc antibody regions to confer effector function
    10.
    发明授权
    Engineering Fc antibody regions to confer effector function 有权
    工程化Fc抗体区域以产生效应子功能

    公开(公告)号：US08216574B2

    公开(公告)日：2012-07-10

    申请号：US12565911

    申请日：2009-09-24

    申请人： Jeffrey Stavenhagen ,  Scott Koenig

    发明人： Jeffrey Stavenhagen ,  Scott Koenig

    IPC分类号： A61K39/395 ,  C07K16/00

    CPC分类号： C07K16/30 ,  C07K16/00 ,  C07K16/283 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/30 ,  G01N33/574

    摘要： The present invention relates to molecules having a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region. These modified molecules confer an effector function to a molecule, where the parent molecule does not detectably exhibit this effector function. In particular, the molecules of the invention have an increased effector cell function mediated by a FcγR, such as, but not limited to, ADCC. In one embodiment, the variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention have particular utility in treatment, prevention or management of a disease or disorder, such as cancer, in a sub-population of patients, wherein the target antigen is expressed at low levels in the target cell population, in particular, in patients refractory to treatment with an existing therapeutic antibody due to the low level of target antigen expression on the cancer or associated cells.

    摘要翻译： 本发明涉及具有变体Fc区的分子，其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰。 这些修饰的分子赋予分子的效应子功能，其中母体分子不可检测地显示出该效应子功能。 特别地，本发明的分子具有由FcγR介导的增加的效应细胞功能，例如但不限于ADCC。 在一个实施方案中，相对于包含野生型Fc区的可比分子，变体Fc区以更高的亲和力结合FcγRIIIA和/或FcγRIIA。 本发明的分子在患者的亚群中治疗，预防或治疗疾病或病症（例如癌症）具有特别的用途，其中目标抗原在靶细胞群体中以低水平表达，特别是， 在由于癌细胞或相关细胞上的靶抗原表达水平低的现有治疗性抗体治疗难治的患者中。